According to data from the National Cancer Institute, lung cancer is the third most common type of cancer in the United States. However, with the advancement of treatment technology in the past two decades, the treatment prospects for lung cancer patients have become increasingly optimistic.

20th Anniversary of EGFR Target Discovery: A Milestone in Lung Cancer Treatment

May 2024 marks the 20th anniversary of the discovery of the first lung cancer target EGFR. Dr. Lauren Byers from Anderson Cancer Center said, "The discovery of EGFR targets has opened up a new era in lung cancer treatment." Nowadays, when patients are diagnosed with lung cancer, the first step is usually genetic testing to identify the cancer type and develop personalized treatment plans, thereby enhancing treatment efficacy.

Targeted therapy: precision therapy based on lung cancer types

Lung cancer is mainly divided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Among them, about 85% of patients are NSCLC, while the remaining 15% are SCLC. Non small cell lung cancer patients often experience mutations or fusions in specific genes, which provide precise targets for targeted therapy. By "shutting down" these mutated genes at the genetic level, targeted drugs can effectively inhibit the growth of cancer cells. For small cell lung cancer, although its genetic changes cannot be directly targeted, the research focus has shifted to cancer cell surface proteins, which are controlled by inhibiting specific genes.

Targeted therapy options for NSCLC: precision guided biomarkers

The detection of biomarkers is crucial in the treatment of non-small cell lung cancer. About 40% to 50% of NSCLC patients carry biomarker mutations, making them candidates for targeted therapy. These mutations include genes such as ALK, BRAF, EGFR, HER2, KRAS, etc. The mutation rates of EGFR and KRAS vary among different populations. For example, EGFR mutations are more common in Asian patients, while KRAS and BRAF mutations are more common in patients with a history of smoking.

Side effects of targeted therapy for NSCLC: Side effect management and advances in new drugs

Although there are various types of targeted drugs with different side effects, most common side effects (such as rash, dry skin, diarrhea) can be effectively managed. With the progress of research, the side effects of new generation targeted drugs such as osimertinib have been greatly reduced, providing patients with higher treatment tolerance. Doctors can also help patients by adjusting the dosage.

SCLC Targeted Therapy: New Hope for Targeting Cancer Cell Surface Proteins

Although the treatment progress of small cell lung cancer is relatively slow, recent research has brought breakthrough progress. The therapeutic strategies targeting surface proteins of cancer cells, especially antibody drug conjugates, have brought new hope for the treatment of small cell lung cancer patients. This type of drug reduces its impact on healthy cells by directly delivering chemotherapy drugs into cancer cells. Meanwhile, bispecific T-cell immunotherapy such as Tarlatamab can guide the patient's immune system to attack cancer cells expressing DLL3 and has been approved for use by the FDA.

The future of targeted therapy for lung cancer: more choices and wider applicability

Targeted therapy for lung cancer is making breakthroughs in the following three directions. Firstly, targeted therapy for early lung cancer has shown encouraging results. By adding targeted drugs after surgery or chemotherapy, cancer recurrence can be effectively reduced, bringing better prognosis to patients. Secondly, the development of next-generation targeted drugs continues to expand the applicable population and achieve longer lasting effects through more precise targeting, while significantly reducing side effects. New therapeutic targets and innovative therapies provide patients with more choices, helping them to occupy a more advantageous position in the fight against lung cancer.

In short, with the continuous progress of targeted therapy for lung cancer, Anderson Cancer Center will continue to promote new drug development and innovative treatments, committed to bringing better quality of life and treatment hope to patients.